| 35.05 0.91 (2.67%) | 10-15 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 43.85 |
1-year : | 51.22 |
| Resists | First : | 37.54 |
Second : | 43.85 |
| Pivot price | 35.61 |
|||
| Supports | First : | 33.68 |
Second : | 31.29 |
| MAs | MA(5) : | 34.42 |
MA(20) : | 35.25 |
| MA(100) : | 34.18 |
MA(250) : | 33.66 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 30.7 |
D(3) : | 30.3 |
| RSI | RSI(14): 54.6 |
|||
| 52-week | High : | 46.47 | Low : | 22.61 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TGTX ] has closed above bottom band by 36.5%. Bollinger Bands are 33.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.33 - 35.58 | 35.58 - 35.77 |
| Low: | 33.52 - 33.78 | 33.78 - 33.98 |
| Close: | 34.71 - 35.11 | 35.11 - 35.43 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Tue, 30 Sep 2025
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You - simplywall.st
Tue, 23 Sep 2025
19,900 Shares in TG Therapeutics, Inc. $TGTX Bought by Strs Ohio - MarketBeat
Thu, 04 Sep 2025
TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Wed, 03 Sep 2025
TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback - Yahoo Finance
Tue, 05 Aug 2025
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 159 (M) |
| Shares Float | 135 (M) |
| Held by Insiders | 9.7 (%) |
| Held by Institutions | 64.5 (%) |
| Shares Short | 23,610 (K) |
| Shares Short P.Month | 24,510 (K) |
| EPS | 0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.89 |
| Profit Margin | 13.3 % |
| Operating Margin | 24.6 % |
| Return on Assets (ttm) | 9.7 % |
| Return on Equity (ttm) | 26.6 % |
| Qtrly Rev. Growth | 92 % |
| Gross Profit (p.s.) | 2.48 |
| Sales Per Share | 2.86 |
| EBITDA (p.s.) | 0.54 |
| Qtrly Earnings Growth | 325 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | 92.23 |
| PEG Ratio | 0 |
| Price to Book value | 18.44 |
| Price to Sales | 12.24 |
| Price to Cash Flow | -94.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|